Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: A randomized study from the Groupe d'Etude des Lymphomes Folliculaires

Journal of Clinical Oncology

Volumn 15, Issue 3, 1997, Pages 1110-1117

  Brice, P ^a   Bastion, Y ^a   Lepage, E ^a   Brousse, N ^a   Haioun C ^a   Moreau, P ^a   Straetmans, N ^a   Tilly, H ^a   Tabah, I ^a   Solal Celigny P ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; BIOLOGICAL RESPONSE MODIFIER; PREDNIMUSTINE; RECOMBINANT ALPHA2B INTERFERON;

ADULT; AGED; ARTICLE; BODY BURDEN; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; FOLLICULAR LYMPHOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031050192     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.3.1110     Document Type: Article

References (29)

1. National Cancer Institute sponsored study of classification of non Hodgkin's lymphomas: Summary and description of a working formulation for clinical usage. Cancer 49:2112-2135, 1982
2. Harris NL, Jaffe ES, Stein H, et al: A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 84:1361-1392, 1994
3. Soubeyran P, Cabanillas F, Sheng Lee M: Analysis of the expression of the hybrid gene bcl-2/IgH in follicular lymphomas. Blood 81:122-127, 1993
4. Portlock CS, Rosenberg SA: No initial therapy for stage III and IV non-Hodgkin's lymphomas of favorable histologic types. Ann Intern Med 90:10-13, 1979
5. Johnson PWN, Rohatiner AZS, Whelan JS, et al: Patterns of survival in patients with recurrent follicular lymphoma: A 20 year study from a single center. J Clin Oncol 13:140-147, 1995
6. Besa PC, McLaughlin PW, Cox JD, et al: Long term assessment of patterns of treatment failure and survival in patients with stage I or II follicular lymphoma. Cancer 75:2361-2367, 1995
7. Horning SJ, Rosenberg SA: The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med 311:1471-1475, 1984
8. Young RC, Longo DL, Glatstein E, et al: The treatment of indolent lymphomas: Watchful waiting versus aggressive combined modality treatment. Semin Hematol 25:11-16, 1988
9. Gallagher CJ, Gregory WM, Jones AE, et al: Follicular lymphoma: Prognostic factors for response and survival. J Clin Oncol 4:1470-1480, 1986
10. Coiffier B, Bastion Y, Berger F, et al: Prognostic factors in follicular lymphoma. Semin Oncol 20:89-95, 1993
11. Hermans J, Krol ADG, Van Groningen K, el al: International prognostic index for aggressive non-Hodgkin's lymphoma is valid for all malignancy grades. Blood 86:1460-1463, 1995
12. Gandara DR, Wold HG, Redmond J, et al: Prednimustine in refractory non-Hodgkin's lymphoma: A phase II study of the Northern Californian Oncology Group. Semin Oncol 13:14-18, 1986
13. Foon KA, Sherwin SA, Abrams PG, et al: Treatment of advanced non-Hodgkin's lymphoma with recombinant leukocyte A interferon. N Engl J Med 311:1148-1152, 1984
14. O'Connell MJ, Colgan JP, Oken MM, et al: Clinical trial of recombinant leukocyte A interferon as initial therapy for favorable histology non-Hodgkin's lymphoma and chronic lymphocytic leukemia, an ECOG pilot study. J Clin Oncol 4:128-136, 1986
15. Price CGA, Rohatiner AZS, Steward W, et al: Interferon alfa-2b in addition to chlorambucil in the treatment of follicular lymphoma: Preliminary results of a randomized trial in progress. Eur J Cancer 27:S34-S36, 1991 (suppl 4)
16. Solal-Céligny P, Lepage E, Brousse N, et al: Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. N Engl J Med 329:1608-1614, 1993
17. Kaplan ES, Meier P: Non parametric estimation from incomplete observations. J Am Stat Assoc 53:457-461, 1958
18. Cox DR: Regression models and life tables. J Stat Soc 34:187-220, 1972
19. Morel P, Dupriez B, Plantier-Colcher I, et al: Long-term outcome of follicular low-grade lymphoma: A report of 91 patients. Ann Hematol 66:303-308, 1993
20. Horning SJ: Natural history of therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 20:75-88, 1993 (suppl 5)
21. Romaguera JE, McLaughlin P, North L, et al: Multivariate analysis of prognostic factors in stage IV follicular low-grade lymphoma: A risk model. J Clin Oncol 9:762-769, 1991
22. Chisesi T, Congiu M, Contu A, et al: Randomized study of chlorambucil (CB) compared to interferon (alfa-2b) combined with CB in low-grade non-Hodgkin's lymphoma: An interim report of a randomized study. Eur J Cancer 27:S31-S33, 1991 (suppl 4)
23. Soubeyran P, Eghbali H, Bonichon F, et al: Low-grade follicular lymphomas: Analysis of prognosis in a series of 281 patients. Eur J Cancer 27:1606-1613, 1991
24. Rohatiner AZS, Johnson PWM, Price CGA, et al: Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma. J Clin Oncol 12:1177-1184, 1994
25. Smalley RV, Andersen JW, Hawkins MJ, et al: Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma. N Engl J Med 327:1336-1341, 1992
26. McLaughlin P, Cabanillas F, Hagemeister FB, et al: CHOP-Bleo plus interferon for stage IV low-grade lymphoma. Ann Oncol 4:205-211, 1993
27. Van Leeuwen FE, Klokman WJ, Hagenbeek A, et al: Second cancer risk following Hodgkin's disease: A 20-year follow-up study. J Clin Oncol 12:312-325, 1994
28. Bastion Y, Brice P, Haïoun C, et al: Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma. Blood 88:3257-3262, 1995
29. Morel P, Laporte JP, Noel MP, et al: Autologous bone marrow transplantation as consolidation therapy may prolong remission in newly diagnosed high-risk follicular lymphoma: A pilot study of 34 cases. Leukemia 9:576-582, 1995